Apr 13 |
AbbVie keeps Humira market share near 100% despite biosimilars: report
|
Apr 8 |
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
|
Apr 8 |
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
|
Mar 8 |
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
|
Feb 24 |
Organon Stock Is Still Worth A Look
|
Feb 20 |
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
|
Feb 16 |
Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
|
Feb 15 |
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Feb 15 |
Organon & Co. (OGN) Q4 2023 Earnings Call Transcript
|
Feb 15 |
Organon nears five-month high after Q4 beat
|